Faute de régulation, la communauté est aux prises avec une perte des valeurs et le crime organisé.

Un microbiologiste du ministère n'avait rien trouvé d'anormal un an avant les révélations d'Enquête.

Karine Boivin Roy se dit réceptive aux inquiétudes quant au guichet unique pour le logement abordable.

Paul St-Pierre Plamondon sera le premier chef de parti à discuter de questions internationales avec l’organisme.

Un homme dans la vingtaine a perdu la vie après avoir été heurté tôt vendredi matin sur le boulevard Taschereau, dans le quartier LeMoyne à Longueuil, par un conducteur qui a pris la fuite.

Un homme de 59 ans repose dans un état critique après que son automobile ait percuté une terrasse sur la rue Sherbrooke Ouest, dans l’arrondissement montréalais de Côte-des-Neiges–Notre-Dame-de-Grâce, dans la nuit de jeudi à vendredi.

NOT FOR DISTRIBUTION TO THE UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) — Newcore Gold Ltd. (“Newcore” or the “Company”) (TSX-V: NCAU, OTCQX: NCAUF) is pleased to announce that, in connection with its previously announced bought deal financing (the “Offering”), it has entered into an amended agreement with Haywood Securities Inc., on its behalf and on behalf of a syndicate of underwriters (collectively, the “Underwriters”), to increase the size of the Offering pursuant to which the Underwriters have agreed to purchase, on a bought-deal basis, 28,310,000 common shares of the Company (the “Common Shares”) at a price of $0.53 per Common Share for aggregate gross proceeds to the Company of $15,004,300. The Company intends to use the net proceeds of the Offering to fund exploration and development activities at the Company’s Enchi Gold Project in Ghana, as well as for general corporate and working capital purposes as described in the Offering Document (as defined below). The Offering is expected to close on or about May 28, 2026, or such other date as may be agreed to by the Company and the Underwriters (the “Closing”). Closing is subject to certain customary conditions, including, but not limited to, the receipt of all necessary approvals including the conditional approval of the TSX Venture Exchange and the applicable securities regulatory authorities. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (“NI 45-106”), the Offering is being made to purchasers’ resident in Canada, except Québec, pursuant to the listed issuer financing exemption under Part 5A of NI- 45-106, as amended and supplemented by Coordinated Blanket Order 45-935 Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the “Listed Issuer Financing Exemption”). The Common Shares offered under the Listed Issuer Financing Exemption will not be subject to a hold period in accordance with applicable Canadian securities laws. The securities being offered have not been, nor will they be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any applicable securities laws of any state of the United States and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent such registration or an applicable exemption from such registration requirements. This release does not constitute an offer for sale or the solicitation of an offer to buy any of the securities in the United States or to, or for the account or benefit of, a U.S. person. “U.S. person” and “United States” are as defined in Regulation S under the U.S. Securities Act. There is an amended and restated offering document (the “Offering Document”) related to the Offering that can be accessed under the Company’s profile on SEDAR+ at www.sedarplus.ca and on the Company’s website at newcoregold.com. Prospective investors should read this Offering Document before making an investment decision. About Newcore Gold Ltd. Newcore Gold is advancing its Enchi Gold Project located in Ghana, Africa’s largest gold producer (1). Newcore Gold offers investors a unique combination of top-tier leadership, who are aligned with shareholders through their 13% equity ownership, and prime district scale exploration opportunities. Enchi’s 248 km2 land package covers 40 kilometres of Ghana’s prolific Bibiani Shear Zone, a gold belt which hosts several multi-million-ounce gold deposits, including the Chirano mine 50 kilometres to the north. Newcore’s vision is to build a responsive, creative and powerful gold enterprise that maximizes returns for shareholders.(1) Source: Production volumes for 2024 as sourced from the World Gold Council. On Behalf of the Board of Directors of Newcore Gold Ltd. Luke AlexanderPresident, CEO & Director For further information, please contact: Mal Karwowska | Vice President, Corporate Development and Investor Relations+1 604 484 4399info@newcoregold.com www.newcoregold.com   Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements This news release includes statements that contain “forward-looking information” within the meaning of the applicable Canadian securities legislation (“forward-looking statements”). All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussion with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often, but not always using phrases such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: receipt of all approvals related to the Offering; the intended use of proceeds from the Offering; exercise of the Underwriters’ Option; and the expected terms and closing of the Offering. These forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business. The assumptions underlying the forward-looking statements are based on information currently available to Newcore. Although the forward-looking statements contained in this news release are based upon what management of Newcore believes, or believed at the time, to be reasonable assumptions, Newcore cannot assure its shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Forward-looking information also involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among others: the conditions to closing of the Offering may not be satisfied; management’s broad discretion regarding the use of proceeds of the Offering; the Company may require additional financing from time to time in order to continue its operations which may not be available when needed or on acceptable terms and conditions; risks related to the speculative nature of Newcore’s business; Newcore’s formative stage of development; Newcore’s financial position; possible variations in mineralization, grade or recovery rates; actual results of current exploration activities; fluctuations in general macroeconomic conditions; fluctuations in securities markets; fluctuations in spot and forward prices of gold and other commodities; fluctuations in currency markets (such as the Canadian dollar to United States dollar exchange rate); change in national and local government, legislation, taxation, controls, regulations and political or economic developments; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, unusual or unexpected geological formations); the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); and title to properties. Forward-looking statements contained herein are made as of the date of this news release and Newcore disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results, except as may be required by applicable securities laws. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The post Newcore Gold Announces Upsized $15 Million Bought Deal Financing appeared first on Montreal Gazette.

NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) — Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives. The visit follows recent U.S. policy developments supporting increased research collaboration, regulatory review pathways, and clinical investigation involving psychedelic compounds, including ibogaine. As part of the Company’s engagement efforts, Psyence BioMed Chief Executive Officer Jody Aufrichtig recently submitted a formal letter to President Donald J. Trump and U.S. Secretary of Health and Human Services Robert F. Kennedy Jr., applauding the Administration’s leadership in advancing research initiatives involving psychedelic compounds and expanding pathways for scientific collaboration and innovation. The purpose of the Company’s upcoming U.S. engagement initiative is to educate and inform stakeholders on the complexity, regulatory considerations, and scientific infrastructure required to manufacture pharmaceutical-grade ibogaine under Good Manufacturing Practice (“GMP”) standards suitable for regulated clinical research. Through its strategic investment in PsyLabs, Psyence BioMed has established active ibogaine operations and manufacturing capabilities in Africa – the natural and original source of ibogaine. The Company believes it is among a limited number of organizations globally capable of producing natural, pharmaceutical-grade ibogaine at scale under pharmaceutical compliant GMP conditions. PsyLabs operates a GMP-compliant facility in Southern Africa focused on the cultivation, extraction, purification, and manufacturing of highly purified psychedelic compounds from natural sources. Psyence BioMed’s vertically integrated model supports ethical sourcing practices, quality control, analytical testing, and scalable supply chain management designed to support future clinical research demand. “We believe global interest in ibogaine research continues to accelerate, particularly as policymakers, researchers, and healthcare institutions explore innovative approaches to serious mental health conditions,” said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed. “Our objective during this visit is to contribute constructively to those conversations by sharing our expertise and helping stakeholders better understand the highly specialized process required to produce compliant pharmaceutical-grade ibogaine suitable for regulated research environments.” The Company noted that following recent U.S. policy announcements, it has experienced increased engagement from U.S.-based researchers and institutions seeking information regarding compliant ibogaine manufacturing capabilities and supply availability for future regulated research initiatives. Psyence BioMed believes its operational footprint in Africa, vertically integrated infrastructure, and existing GMP inventory position the Company strategically within the emerging global ibogaine supply ecosystem. Investor and Meeting Inquiries Researchers, institutions, government stakeholders, and industry organizations interested in arranging a meeting or presentation with Psyence BioMed during the Company’s upcoming U.S. visit are encouraged to contact: Michael KyddPublic Affairs Specialistmichael@psyencebiomed.com Learn more about the company at www.psyencebiomed.com and on LinkedIn. Contact Information for Psyence Biomedical Ltd.Email: ir@psyencebiomed.com   Media Inquiries: media@psyencebiomed.com General Information: info@psyencebiomed.com Phone: +1 416-477-1708 Investor Contact:Michael KyddInvestor Relations Advisormichael@psyencebiomed.com About Psyence BioMed  Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics and the manufacturing of pharmaceutical-grade drug candidates. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs. We are committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.  About PsyLabs PsyLabs is a psychedelic Active Pharmaceutical Ingredient (API) development company, federally licensed to cultivate, extract, and export psilocybin mushrooms and other psychedelic compounds including psilocin, mescaline, ibogaine, and dimethyltryptamine (DMT) to legal medical and research markets. The company has successfully exported psilocybin products to Canada, the UK, Portugal, and Slovenia, and supplies purified extracts to its UK-based CMO partner. PsyLabs operates from an ISO 22000 and GMP-compliant facility, ensuring the highest standards of safety and traceability. With a focus on natural compound purification, regulatory support, and global distribution, PsyLabs is expanding its product pipeline to include ibogaine and other next-generation psychedelics.www.psylabs.life Forward Looking Statements This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning. Forward-looking statements in this communication include statements regarding the possible issuance, timing, scope and effect of any U.S. executive action or other governmental measures relating to ibogaine; the potential for such measures to support or accelerate regulated scientific and clinical research into ibogaine; the therapeutic potential of ibogaine and the development of future regulatory pathways for ibogaine-based products; Psyence BioMed’s ability to support global clinical research and future therapeutic development through its investment in PsyLabs and its GMP-compliant manufacturing capabilities; the Company’s ability to develop, maintain and scale an ethically sourced, sustainable and traceable ibogaine supply chain; and the Company’s expected role in supporting future research, development and commercialization activities relating to ibogaine. These forward-looking statements are based on a number of assumptions, including assumptions regarding the development of governmental policy relating to ibogaine, the continuation or expansion of interest in regulated psychedelic research, the availability of lawful research and development pathways, the Company’s ability to maintain required licenses, permits, supply arrangements, third-party relationships and manufacturing capabilities, and the Company’s ability to operate its sourcing and production activities in compliance with applicable legal, regulatory, ethical and environmental standards. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among others, the risk that: (i) any anticipated executive order or other governmental action is not issued, is delayed, or differs from current expectations; (ii) that any such action does not result in expanded research opportunities, clearer regulatory pathways, or any benefit to the Company; (iii) changes in laws, regulations or enforcement priorities in the United States, Southern Africa or other applicable jurisdictions; (iv) the continuing status of ibogaine as a controlled substance in relevant jurisdictions; (v) risks relating to clinical development, regulatory review and approval; (vi) competition and market adoption risks; (vii) and the Company’s ability to maintain compliance with Nasdaq continued listing standards. Additionally, there can be no assurance that the anticipated executive order will be issued, or, if issued, that it will have any particular scope, timing or effect on the Company, its operations, product candidates or applicable regulatory pathways. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-298285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 and other documents filed by Psyence BioMed from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements. The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, ibogaine, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, ibogaine, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to ibogaine stock, inventory, doses or similar references constitute the Company’s best estimates only, as such quantities may vary for several reasons. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations. For purposes of this release, references to “GMP-compliant” mean that the relevant product is produced in a facility designed, operated and controlled in accordance with applicable Good Manufacturing Practice standards. Such references do not, in themselves, constitute a representation that the product, process or facility has been formally certified, approved or endorsed by any particular regulatory authority unless expressly stated. In addition, references to “at Source,” or similar expressions refer to supply activities conducted at the cultivation source in Africa. Such references are intended solely to describe the geographic origin and source-location of cultivation and supply activities, and do not, in themselves, constitute a representation regarding regulatory approval, pharmaceutical certification, product registration, or endorsement by any regulatory authority unless expressly stated. The post Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing appeared first on Montreal Gazette.

The military reprimanded soldiers after they raised concerns about an order to monitor Canadians' online activity during the COVID-19 pandemic, CBC News has learned.

"I bust my ass to do value-added manufacturing, employ people in communities in northern British Columbia. And what did we get? Nothing, nothing, nothing, nothing, nothing," Prince George-based John Brink says of the supports announced for B.C.'s forestry sector.

Members of Canada's largest white nationalist group, Second Sons Canada, have met to train and network with a number of "active clubs" from the United States, and also met with active club movement founder Robert Rundo, who is currently on supervised release for violent offences.

U.S. President Donald Trump departed China on Friday touting business deals that gave markets little to cheer, while Beijing warned Washington about mishandling Taiwan and said its war with Iran should never have started.

After Game 5 of their series against the Buffalo Sabres, the Montreal Canadiens are only one win away from the final four. Brian Wilde has more.

Artemis II crew gets hero's welcome at Canadian Space Agency headquarters in Quebec after historic journey to the far side of the moon.

Abortion pills are the most common method of terminating pregnancies in the US.

An industry body survey found hotels in World Cup host cities see the tournament as a "non-event".

Senator Ronald 'Bato' dela Rosa wanted for alleged role as top enforcer of ex-president Duterte's deadly drug war.

Ronaldo will play in his fifth World Cup and is the record scorer at international level with 143 goals for Portugal.